Results 191 to 200 of about 12,637,526 (357)
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
Hyperlipidemia and the progression of renal disease
, 1988 WF Keane, BL Kasiske, MP O'Donnell
openalex +1 more source
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
Importance of risk factors in the angiographic progression of coronary artery disease
, 1986 Joel S. Raichlen +3 more
openalex +1 more source
Progression and Regression of Atherosclerotic Coronary Artery Disease [PDF]
, 1992 Cara East
openalex +1 more source
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
Preventing the progression of human renal disease: Have rational therapeutic principles emerged?
, 1988 Leon G. Fine
openalex +1 more source
Serum concentration of intercellular adhesion molecule–1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis [PDF]
, 1995 Yukihiro Shimizu +7 more
openalex +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source